Joana Cabral

Joana Cabral

Auto-generated profile, based on publicly available information

Joana Cabral

School of Medicine, Regenerative Medicine Institute (REMEDI), National University of Ireland Galway, Galway, Ireland

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Translational Research
Verified
Journal Article
Closed access
SPSalomé Pinho
Salomé Pinho
SCSandra Carvalho
Sandra Carvalho
JCJoana Cabral
Joana Cabral
CRCelso Reis
Celso Reis
FGFátima Gärtner
Fátima Gärtner

1 March 2013 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
SPSalomé Pinho
Salomé Pinho
Joana FigueiredoJoana Figueiredo
Joana Figueiredo
JCJoana Cabral
Joana Cabral
SCSandra Carvalho
Sandra Carvalho
JDJoana Dourado
Joana Dourado
CRCelso Reis
Celso Reis

13 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSalomé Pinho
Salomé Pinho
POPatrícia Oliveira
Patrícia Oliveira
JCJoana Cabral
Joana Cabral
SCSandra Carvalho
Sandra Carvalho
DHDavid Huntsman
David Huntsman
COCarla Oliveira
Carla Oliveira
N-acetylglucosaminyltransferase-III (GnT-III) is a glycosyltransferase encoded by Mgat3 that catalyzes the addition of β1,4-bisecting-N-acetylglucosamine on N-glycans. GnT-III has been pointed as a metastases suppressor having varying effects on cell adhesion and migration. We have previously described the existence of a functional feedback loop between E-cadherin expression and GnT-III-mediated glycosylation. The effects of GnT-III-mediated glycosylation on E-cadherin expression and cellular phenotype lead us to evaluate Mgat3 and GnT-III-glycosylation role during Epithelial-Mesenchymal-Transition (EMT) and the reverted process, Mesenchymal-Epithelial-Transition (MET). We analyzed the expression profile and genetic mechanism controlling Mgat3 expression as well as GnT-III-mediated glycosylation, in general and specifically on E-cadherin, during EMT/MET. We found that during EMT, Mgat3 expression was dramatically decreased and later recovered when cells returned to an epithelial-like phenotype. We further identified that Mgat3 promoter methylation/demethylation is involved in this expression regulation. The impact of Mgat3 expression variation, along EMT/MET, leads to a variation in the expression levels of the enzymatic product of GnT-III (bisecting GlcNAc structures), and more importantly, to the specific modification of E-cadherin glycosylation with bisecting GlcNAc structures. Altogether, this work identifies for the first time Mgat3 glycogene expression and GnT-III-mediated glycosylation, specifically on E-cadherin, as a novel and major component of the EMT/MET mechanism signature, supporting its role during EMT/MET.

13 December 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ADAna M. Dias
Ana M. Dias
JDJoana Dourado
Joana Dourado
PLPaula Lago
Paula Lago
JCJoana Cabral
Joana Cabral
RMRicardo Marcos-Pinto
Ricardo Marcos-Pinto
SPSalomé Pinho
Salomé Pinho
The incidence of inflammatory bowel disease is increasing worldwide and the underlying molecular mechanisms are far from being fully elucidated. Herein, we evaluated the role of N-glycosylation dysregulation in T cells as a key mechanism in the ulcerative colitis (UC) pathogenesis. The evaluation of the branched N-glycosylation levels and profile of intestinal T cell receptor (TCR) were assessed in colonic biopsies from UC patients and healthy controls. Expression alterations of the glycosyltransferase gene MGAT5 were also evaluated. We demonstrated that UC patients exhibit a dysregulation of TCR branched N-glycosylation on lamina propria T lymphocytes. Patients with severe UC showed the most pronounced defect on N-glycan branching in T cells. Moreover, UC patients showed a significant reduction of MGAT5 gene transcription in T lymphocytes. In this study, we disclose for the first time that a deficiency in branched N-glycosylation on TCR due to a reduced MGAT5 gene expression is a new molecular mechanism underlying UC pathogenesis, being a potential novel biomarker with promising clinical and therapeutic applications.

25 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JDJulio Cesar Madureira De-Freitas-Junior
Julio Cesar Madureira De-Freitas-Junior
SCSandra Carvalho
Sandra Carvalho
ADAna M. Dias
Ana M. Dias
POPatrícia Oliveira
Patrícia Oliveira
JCJoana Cabral
Joana Cabral
SPSalomé Pinho
Salomé Pinho
Changes in glycosylation are considered a hallmark of cancer, and one of the key targets of glycosylation modifications is E-cadherin. We and others have previously demonstrated that E-cadherin has a role in the regulation of bisecting GlcNAc N-glycans expression, remaining to be determined the E-cadherin-dependent signaling pathway involved in this N-glycans expression regulation. In this study, we analysed the impact of E-cadherin expression in the activation profile of receptor tyrosine kinases such as insulin receptor (IR) and IGF-I receptor (IGF-IR). We demonstrated that exogenous E-cadherin expression inhibits IR, IGF-IR and ERK 1/2 phosphorylation. Stimulation with insulin and IGF-I in MDA-MD-435 cancer cells overexpressing E-cadherin induces a decrease of bisecting GlcNAc N-glycans that was accompanied with alterations on E-cadherin cellular localization. Concomitantly, IR/IGF-IR signaling activation induced a mesenchymal-like phenotype of cancer cells together with an increased tumor cell invasion capability. Altogether, these results demonstrate an interplay between E-cadherin and IR/IGF-IR signaling as major networking players in the regulation of bisecting N-glycans expression, with important effects in the modulation of epithelial characteristics and tumor cell invasion. Here we provide new insights into the role that Insulin/IGF-I signaling play during cancer progression through glycosylation modifications.